Nowadays it is well known that PARP-is induce apoptosis in BRCA-deficient cancer cells, so this mechanism is evidence that these molecules are relevant as targeted therapy in BRCA-mutated cancer [24]. The gene discussed is PARP1; the disease is cancer.